Article
P50: A candidate ERP biomarker of prodromal Alzheimer's disease
Brain Research
(2015)
Abstract
Introduction:
Reductions of cerebrospinal fluid (CSF) amyloid-beta (Aβ42) and elevated phosphorylated-tau (p-Tau) reflect in vivo Alzheimer׳s disease (AD) pathology and show utility in predicting conversion from mild cognitive impairment (MCI) to dementia. We investigated the P50 event-related potential component as a noninvasive biomarker of AD pathology in non-demented elderly.
Methods:
36 MCI patients were stratified into amyloid positive (MCI-AD, n=17) and negative (MCI-Other, n=19) groups using CSF levels of Aβ42. All amyloid positive patients were also p-Tau positive. P50s were elicited with an auditory oddball paradigm.
Results:
MCI-AD patients yielded larger P50s than MCI-Other. The best amyloid-status predictor model showed 94.7% sensitivity, 94.1% specificity and 94.4% total accuracy.
Discussion:
P50 predicted amyloid status in MCI patients, thereby showing a relationship with AD pathology versus MCI from another etiology. The P50 may have clinical utility for inexpensive pre-screening and assessment of Alzheimer׳s pathology.
Keywords
- P50,
- Alzheimer׳s disease (AD),
- Event-related potential (ERP),
- Auditory oddball paradigm,
- Cerebrospinal fluid biomarkers,
- Amyloid-beta
Disciplines
Publication Date
January 10, 2015
DOI
10.1016/j.brainres.2015.07.054
Citation Information
Deborah L. Green, Lisa Payne, Robi Polikar, Paul J. Moberg, et al.. "P50: A candidate ERP biomarker of prodromal Alzheimer's disease" Brain Research Vol. 1624 (2015) p. 390 - 397 Available at: http://works.bepress.com/robi-polikar/13/